无并发症革兰阴性菌血症7天与14天抗生素治疗的非劣效随机对照试验
本研究为多中心、开放标签、非劣效随机对照试验,纳入604例无并发症革兰阴性菌血症住院患者,随机接受7天或14天覆盖抗生素治疗。主要终点为90天全因死亡、复发、化脓性或远处并发症及再入院或延长住院的复合终点。7天组主要终点发生率为45.8%,14天组为48.3%,风险差-2.6%(95%CI -10.5%至5.3%),非劣效界值为10%,表明7天治疗非劣效于14天。
要点
- 对于临床稳定的无并发症革兰阴性菌血症患者,7天抗生素治疗非劣效于14天。
- 7天组主要终点风险差为-2.6%(95%CI -10.5%至5.3%),非劣效界值10%。
- 短期治疗可缩短恢复基线功能状态的时间,且未增加不良事件。
核心结论
- 在住院的革兰阴性菌血症患者中,若第7天前达到临床稳定,7天抗生素疗程非劣效于14天疗程。
研究设计与样本
- 多中心、随机、开放标签、非劣效试验,纳入604例(7天组306例,14天组298例),在以色列和意大利3个中心于2013年1月至2017年8月进行。
主要发现
- 主要终点在7天组发生140/306例(45.8%),14天组144/298例(48.3%),风险差-2.6%(95%CI -10.5%至5.3%)。
- 其他结局和不良事件无显著差异,但短期治疗组恢复基线功能状态的时间更短。
关键数值与推荐
- 非劣效界值设为10%。
- 主要终点为90天全因死亡、复发、化脓性或远处并发症、再入院或延长住院(>14天)的复合终点。
- 感染源为尿路者411/604例(68%),致病菌主要为肠杆菌科(543/604例,90%)。
临床怎么用
- 对于临床稳定的无并发症革兰阴性菌血症患者,可将抗生素疗程缩短至7天,作为抗菌药物管理干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited. METHODS: This was a randomized, multicenter, open-label, noninferiority trial. Inpatients with gram-negative bacteremia, who were afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 days (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative, or distant complications; and readmission or extended hospitalization (>14 days). The noninferiority margin was set at 10%. RESULTS: We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in 3 centers in Israel and Italy. The source of the infection was urinary in 411 of 604 patients (68%); causative pathogens were mainly Enterobacteriaceae (543/604 [90%]). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140 of 306 patients (45.8%) in the 7-day group vs 144 of 298 (48.3%) in the 14-day group (risk difference, -2.6% [95% confidence interval, -10.5% to 5.3%]). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short-course therapy arm. CONCLUSIONS: In patients hospitalized with gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was noninferior to 14 days. Reducing antibiotic treatment for uncomplicated gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention. CLINICAL TRIALS REGISTRATION: NCT01737320.
引用
- Yahav D, Franceschini E, Koppel F, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019. PMID: 30535100. doi:10.1093/cid/ciy1054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。